Objective: To determine prognostic factors for progression-free survival (PFS) and overall survival (OS) for stage I-II cervical-cancer patients treated using computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT).
Methods: A total of 150 patients were treated for Stage I-II cervical cancer using CT-planned BT between 4/2004 and 10/2014. Of these, 128 were eligible for inclusion. Kaplan-Meier local control (LC), pelvic control (PC), overall survival (OS), and PFS estimates were calculated.
Results: After a median follow-up of 30months, the 2-year LC rate was 96%, PFS was 88%, and OS was 88%. Overall, 18 patients (14%) experienced any recurrence (AR), 8 had distant recurrence only and 10 had a combination of local, pelvic, regional, and distant recurrence. No patients had LR only. A prognostic factor for AR was tumor size >4cm (p=0.01). Patients with tumors >4cm were 3.3 times more likely to have AR than those with tumors ≤4cm (hazard ratio [HR]=3.3; 95% confidence interval [CI] 1.28-9.47). Point A was 85% of prescription for tumors < 4 cm and decreased approximately 3% over 5 fractions compared to 90% of prescription for tumors > 4 cm that decreased approximately 4% over 5 fractions. Two patients (2%) experienced grade≥2 late toxicity. There were no acute or late grade≥3 toxicities.
Conclusion: CT-planned BT resulted in excellent local control and survival. Large tumor size was associated with an increased risk of recurrence outside the radiation field and worse PFS and OS. A volume-optimized plan treated a smaller area than a point A standard plan for patients with Stage I-II cervical cancer that have received chemoradiation. Given the outstanding LC achieved with modern therapy including chemoradiation, HDR, and image-based BT, further efforts to combat spread outside the radiation field with novel therapies are warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2016.09.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Value of Abnormal Prothrombin and Carbohydrate Antigen 125 in the Diagnosis of Patients With Gallbladder Cancer.
Am Surg
January 2025
Department of Hepatobiliary and Pancreatic Surgery, East Hospital of Yantai Mountain Hospital, Yantai, China.
Objective: This study was aimed at ascertaining the application value of abnormal prothrombin (PIVKA-II) and carbohydrate antigen 125 (CA125) in gallbladder cancer (GBC) diagnosis.
Methods: A total of 70 GBC patients, 70 patients with benign gallbladder diseases (gallbladder stones and gallbladder polyps), and 70 normal health examination people were selected as the malignant, benign, and normal groups, respectively. The differences in serum levels and positive rates of PIVKA-II and CA125 were compared.
Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study.
Arch Gynecol Obstet
January 2025
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, No.44, Xiaoheyan Road, Dadong District, Shenyang, Liaoning, 110042, People's Republic of China.
Objective: The optimal initial management strategy for cervical cancer with lymph node metastases (LNM) remains a topic of ongoing debate. This study aimed to explore the correlation between surgery followed by postoperative radiotherapy (PORT) and definitive radiotherapy (RT), as well as their impact on the prognosis of patients with LNM.
Methods: Patients with positive lymph nodes (PLNs) in 2009 FIGO stage I-III cervical cancer were selected from SEER database.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: In Alzheimer's disease (AD), specific brain regions become vulnerable to pathology while others remain resilient. New methods of imaging such as highly multiplexed immunofluorescence (MxIF) provide an abundance of spatial information, while analytical techniques like machine learning (ML) can address questions of cellular contributors to this regional vulnerability.
Method: We performed MxIF staining for 26 markers and compared postmortem human samples from an AD-susceptible brain area, the prefrontal cortex (PFC, Brodmann's areas 9, 10 or 46) to an AD-resilient brain area, the primary visual cortex (V1, area 17).
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Virginia, Charlottesville, VA, USA.
Background: Tau phosphorylated at threonine-217 (tau), which can be measured in plasma and CSF using antibodies, is one of the most promising early biomarkers for Alzheimer's disease (AD). Little was known, however, about the cellular and subcellular distributions of tau, how those levels change during disease progression, the factor(s) that provoke tau accumulation, or functional consequences of tau phosphorylation at T217. This study addressed all of those issues.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Michigan State University, Grand Rapids, MI, USA.
Background: The pathological correlate most tightly associated with cognitive decline in AD is synapse loss. The presence of pathological tau significantly correlates with synaptotoxicity and cognitive decline in AD, yet it is currently unclear how pathological tau causes synapse loss. Within the brain, complement component C1q coats the outer membrane of weak or damaged synapses, resulting in the phagocytic removal of tagged synapses by microglia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!